Twist Bioscience director sells 12,000 shares

Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale.

Rhea-AI Filing Summary

Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale. Johannessen exercised employee stock options for 12,000 shares of common stock at $14.00 per share, increasing his holdings to 29,754 shares. On the same day, he completed an open-market sale of 12,000 common shares at an average price of $56.12 per share, leaving him with 17,754 shares held directly after the transactions. The options exercised had vested in stages over several years, subject to his continuous service.

Insider Trade Summary

Exercise and Sale: 12,000 shares ($505K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider JOHANNESSEN JAN

Role Director

Sold 12,000 shs ($673K)

Approx. gross sale proceeds $673K

Approx. exercise cost $168K

Approx. pre-tax spread $505K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	12,000	$0.00	$0.00
Exercise	Common Stock	12,000	$14.00	$168K
Sale	Common Stock	12,000	$56.12	$673K

Holdings After Transaction: Employee Stock Option (right to buy) — 10,304 contracts (Direct); Common Stock — 17,754 shares (Direct)

Footnotes (1)

1. F1. 1/3rd of the shares subject to the option vested and became exercisable on October 30, 2019, and 1/3rd of the shares subject to the option vested and became exercisable on each annual anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Shares sold: 12,000 shares Sale price: $56.12 per share Options exercised: 12,000 shares +3 more

6 metrics

Shares sold 12,000 shares Open-market sale of common stock

Sale price $56.12 per share Average price for 12,000 sold shares

Options exercised 12,000 shares Employee stock option exercise

Option strike price $14.00 per share Exercise price for employee stock option

Shares after exercise 29,754 shares Direct holdings after option exercise, before sale

Shares after sale 17,754 shares Direct holdings after sale of 12,000 shares

Key Terms

open-market sale, Employee Stock Option (right to buy), Exercise or conversion of derivative security, Common Stock

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Employee Stock Option (right to buy) financial

"security_title": "Employee Stock Option (right to buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Twist Bioscience (TWST) director Jan Johannessen report?

Jan Johannessen reported exercising options for 12,000 Twist Bioscience common shares and selling 12,000 shares in an open-market transaction. These moves reflect an exercise-and-sell pattern, combining a derivative exercise with a same-day disposition of the acquired stock.

How many Twist Bioscience (TWST) shares did Jan Johannessen sell and at what price?

Johannessen sold 12,000 Twist Bioscience common shares in an open-market sale at an average price of $56.12 per share. This transaction converted part of his equity position into cash while maintaining a remaining direct shareholding after the sale.

What stock options did Jan Johannessen exercise in the latest Twist Bioscience (TWST) Form 4?

He exercised employee stock options covering 12,000 Twist Bioscience common shares at a strike price of $14.00 per share. The option grant vested in annual one-third increments, contingent on his continuous service through each specified vesting date.

How many Twist Bioscience (TWST) shares does Jan Johannessen hold after these transactions?

Following the reported option exercise and open-market sale, Johannessen directly holds 17,754 Twist Bioscience common shares. This figure represents his remaining non-derivative ownership position as disclosed after completing both transactions on the reported transaction date.

What vesting terms applied to Jan Johannessen’s exercised Twist Bioscience (TWST) stock options?

The option grant vested in three equal tranches: one-third on October 30, 2019, and one-third on each annual anniversary afterward. Vesting required Johannessen’s continuous service with Twist Bioscience through each respective vesting date before becoming exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHANNESSEN JAN

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		M		12,000	A	$14	29,754	D
Common Stock	05/12/2026		S		12,000	D	$56.12	17,754	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$14	05/12/2026		M		12,000		(1)	10/30/2018	Common Stock	12,000	$0	10,304	D

Explanation of Responses:

1. 1/3rd of the shares subject to the option vested and became exercisable on October 30, 2019, and 1/3rd of the shares subject to the option vested and became exercisable on each annual anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Jan Johannessen	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)